Landmark Crohn's trials in plain English

The studies that shaped how Crohn's is treated today, what they found and what they did not show

7 min read Updated 16 November 2026 24 sources

In short

  • ACCENT I and II showed that people who respond to infliximab do better if they keep having it regularly.
  • SONIC found infliximab plus azathioprine worked better than either medicine alone in people new to both.
  • CHARM, GEMINI 2 and UNITI were the key trials behind adalimumab, vedolizumab and ustekinumab.
  • CALM showed that adjusting treatment using blood and poo tests, not just symptoms, led to more bowel healing.
  • PROFILE, a UK trial, found strong treatment from diagnosis kept far more people well, with fewer operations five years on.
  • These trials explain why your team may suggest something. They do not decide what is right for you.
On this page
  1. What makes a trial 'landmark'?
  2. ACCENT I and II (2002 and 2004): should infliximab be given long term?
  3. SONIC (2010): why two medicines can work better than one
  4. Newer biologics, and comparing them head to head
  5. CALM and POCER: treating by tests, not just symptoms
  6. PROFILE: starting strong treatment from diagnosis
  7. LIR!C and the CDED trial: surgery and diet
  8. Sources

What makes a trial 'landmark'?

The trials below are randomised controlled trials: people were put into treatment groups by chance and the results compared, often against a placebo (dummy treatment). The NHS explains that this is how new treatments are tested fairly. The trials here are among the most widely quoted in Crohn's research. For how to judge any trial yourself, see our guide to reading medical evidence.1

A note on reading this page: these studies explain the reasoning behind common treatments. They do not tell you what you personally should take. That is a decision for you and your IBD team.23

ACCENT I and II (2002 and 2004): should infliximab be given long term?

Infliximab was one of the first biologic medicines for Crohn's. ACCENT I took 573 people with active Crohn's who had a first infusion. Among those who improved, people who carried on having regular infusions were more likely to be in remission at 30 and 54 weeks, more likely to come off steroids, and stayed well for longer than those switched to placebo. Serious infections were no more common.4

ACCENT II did the same for people with Crohn's fistulas (tunnels from the bowel, often near the bottom). Among those who responded at first, people who kept having infliximab stayed well for much longer. After a year, 36 in 100 had no draining fistulas, compared with 19 in 100 on placebo.5

Together these trials set the pattern of regular, ongoing biologic treatment rather than one-off courses.45

SONIC (2010): why two medicines can work better than one

SONIC compared infliximab alone, azathioprine (an immunosuppressant tablet) alone, and the two together, in 508 adults with moderate to severe Crohn's who had never had either kind of medicine. At 26 weeks, about 57 in 100 people on the combination were in remission without steroids, compared with 44 in 100 on infliximab alone and 30 in 100 on azathioprine alone. Serious infections were similar across the groups.6

This is one reason why some people starting infliximab are offered a second 'helper' medicine alongside it. Whether it suits you is something to talk through with your IBD team.6

Newer biologics, and comparing them head to head

Each newer biologic was tested in large placebo-controlled trials. A common design was to give everyone the medicine first, then randomly switch some of the people who responded to placebo, to see whether carrying on kept them well.789

  • CHARM (2007), adalimumab (Humira and biosimilars): among people who responded, 36 to 41 in 100 who kept taking it were in remission at about a year, compared with 12 in 100 on placebo. A more frequent schedule worked no better.
  • GEMINI 2 (2013), vedolizumab (Entyvio): more people reached remission than on placebo at 6 weeks, and responders who stayed on it were more likely to be in remission at a year. Serious side effects and infections were somewhat more common than on placebo in this trial.
  • UNITI (2016), ustekinumab (Stelara): a first drip helped more people improve than placebo, and about half of responders who kept having injections were in remission at 44 weeks, against about 36 in 100 on placebo.
  • ADVANCE and MOTIVATE (2022), risankizumab (Skyrizi): more remission and more improvement seen on camera tests than placebo at 12 weeks, including in people for whom other biologics had failed.
  • U-EXCEL, U-EXCEED and U-ENDURE (2023), upadacitinib (Rinvoq), a daily tablet: better than placebo both for settling Crohn's and keeping it settled for a year. Some side effects, such as shingles, liver changes and a few bowel perforations, were seen more on the medicine.7891011

REACH (2007) tested infliximab in 112 children with moderate to severe Crohn's. After the first three doses, 88 in 100 had improved and 59 in 100 were in remission, and children who kept having it more often did better at one year than those who had it less often.12

Most early trials compared a medicine with placebo, which does not tell you which medicine is best. SEAVUE (2022) compared ustekinumab with adalimumab directly in 386 adults who had never had a biologic. At one year, 65 in 100 on ustekinumab and 61 in 100 on adalimumab were in remission, a difference too small to be sure of. Both worked well.13

SEQUENCE (2024) compared risankizumab with ustekinumab in people whose Crohn's had not responded to anti-TNF medicines such as infliximab or adalimumab, or who had side effects from them. Risankizumab was at least as good for remission at 24 weeks, and better at healing the bowel lining at 48 weeks (32 in 100 against 16 in 100). Side effects looked similar.14

A 2026 Cochrane review compared the biologic and newer medicines for Crohn's in adults, including ones never tested against each other. Many were probably or possibly better than placebo, but the strength of evidence varied a lot. The authors called for more head-to-head trials and better long-term safety data.15

CALM and POCER: treating by tests, not just symptoms

CALM (2017) compared two ways of deciding when to step up treatment in 244 adults with active Crohn's who had not had immunosuppressants or biologics before. One group was managed on symptoms alone. The 'tight control' group also had treatment stepped up if blood (CRP) or poo (calprotectin) tests showed inflammation, even if they felt fine. After 48 weeks, 46 in 100 in the tight control group had a healed bowel lining, compared with 30 in 100 in the symptom-only group.16

POCER (2015) looked at people who had had bowel surgery for Crohn's. Those given a colonoscopy at six months, with treatment stepped up if Crohn's had come back, did better at 18 months than those on standard treatment alone. It also showed that even people at lower risk needed monitoring.17

These trials underpin 'treat to target', where your team agrees measurable goals with you. The international STRIDE-II guidance lists normal blood and poo markers as early goals, and a healed bowel lining, no disability and good quality of life as long-term goals.1618

PROFILE: starting strong treatment from diagnosis

PROFILE was run in 40 UK hospitals with 386 people aged 16 to 80 newly diagnosed with active Crohn's. Half started straight away on infliximab plus an immunosuppressant ('top-down'). The other half had the usual 'step-up' approach, starting with milder treatment and moving on if needed. After a year, 79 in 100 in the top-down group had stayed in remission without steroids or surgery, against 15 in 100 in the step-up group, with fewer flares, serious side effects and operations. A blood test that was hoped to predict who needed strong treatment did not help.19

Five years on, there had been 6 Crohn's operations in the top-down group compared with 28 in the step-up group, and fewer hospital admissions and complications. Serious infections and cancers were similar in both groups. The researchers said early strong treatment may change the course of the disease.20

LIR!C and the CDED trial: surgery and diet

LIR!C (2017), a Dutch and UK trial, compared keyhole surgery to remove a short inflamed section (under 40 cm) at the end of the small bowel with infliximab, in adults whose Crohn's had not settled with standard medicines. Quality of life at one year was similar, and the researchers concluded surgery is a reasonable alternative for this group. Over about four years, 37 in 100 people in the infliximab group ended up having surgery anyway. Longer follow-up in 2020 supported these findings.2122

A 2019 trial in 78 children with mild to moderate Crohn's compared the Crohn's Disease Exclusion Diet (CDED), with half of calories from a special drink, against a liquid-only diet (exclusive enteral nutrition). The CDED was much easier to stick to. Both worked well at 6 weeks, but at 12 weeks 76 in 100 children on CDED were still in remission, compared with 45 in 100 in the group that had the liquid-only diet first and then normal food with some liquid feeds. A 2026 European guideline for children now lists both the liquid-only diet and the CDED with partial liquid feeds as preferred first treatments for children at lower risk.2324

Sources

This article is written in our own words from these sources. Each number in the text points to one of them.

  1. NHS Clinical trials Web page, Dec 2022 Read on the NHS website: Clinical trials
  2. NICE Crohn's disease: the care you should expect Web page, May 2019 Read on the NICE website: Crohn's disease: the care you should expect
  3. British Society of Gastroenterology (Gut) British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025 Guideline, Jun 2025 Read on the British Society of Gastroenterology (Gut) website: British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025
  4. The Lancet Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial Study, May 2002 Read the paper: Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
  5. New England Journal of Medicine Infliximab maintenance therapy for fistulizing Crohn's disease (ACCENT II) Study, Feb 2004 Read the paper: Infliximab maintenance therapy for fistulizing Crohn's disease (ACCENT II)
  6. New England Journal of Medicine Infliximab, azathioprine, or combination therapy for Crohn's disease (SONIC) Study, Apr 2010 Read the paper: Infliximab, azathioprine, or combination therapy for Crohn's disease (SONIC)
  7. Gastroenterology Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial Study, Jan 2007 Read the paper: Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial
  8. New England Journal of Medicine Vedolizumab as induction and maintenance therapy for Crohn's disease (GEMINI 2) Study, Aug 2013 Read the paper: Vedolizumab as induction and maintenance therapy for Crohn's disease (GEMINI 2)
  9. New England Journal of Medicine Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease (UNITI) Study, Nov 2016 Read the paper: Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease (UNITI)
  10. The Lancet Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials Study, May 2022 Read the paper: Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trials
  11. New England Journal of Medicine Upadacitinib Induction and Maintenance Therapy for Crohn's Disease (U-EXCEL, U-EXCEED, U-ENDURE) Study, May 2023 Read the paper: Upadacitinib Induction and Maintenance Therapy for Crohn's Disease (U-EXCEL, U-EXCEED, U-ENDURE)
  12. Gastroenterology Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children (REACH) Study, Mar 2007 Read the paper: Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children (REACH)
  13. The Lancet Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease (SEAVUE) Study, Jun 2022 Read the paper: Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease (SEAVUE)
  14. New England Journal of Medicine Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease (SEQUENCE) Study, Jul 2024 Read the paper: Risankizumab versus Ustekinumab for Moderate-to-Severe Crohn's Disease (SEQUENCE)
  15. Cochrane Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis Systematic review, Jun 2026 Read the review: Biologic drugs for induction and maintenance of remission in Crohn's disease: a network meta-analysis
  16. The Lancet Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial Study, Dec 2017 Read the paper: Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial
  17. The Lancet Crohn's disease management after intestinal resection: a randomised trial (POCER) Study, Feb 2015 Read the paper: Crohn's disease management after intestinal resection: a randomised trial (POCER)
  18. Gastroenterology STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD) Guideline, Apr 2021 Read on the Gastroenterology website: STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD)
  19. The Lancet Gastroenterology & Hepatology A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE) Study, May 2024 Read the paper: A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE)
  20. The Lancet Gastroenterology & Hepatology Long-term outcomes of top-down therapy versus a conventional step-up strategy in adults newly diagnosed with Crohn's disease: 5-year follow-up of the PROFILE trial Study, Nov 2026 Read the paper: Long-term outcomes of top-down therapy versus a conventional step-up strategy in adults newly diagnosed with Crohn's disease: 5-year follow-up of the PROFILE trial
  21. The Lancet Gastroenterology & Hepatology Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease (LIR!C) Study, Nov 2017 Read the paper: Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease (LIR!C)
  22. The Lancet Gastroenterology & Hepatology Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: retrospective long-term follow-up of the LIR!C trial Study, Oct 2020 Read the paper: Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: retrospective long-term follow-up of the LIR!C trial
  23. Gastroenterology Crohn's Disease Exclusion Diet Plus Partial Enteral Nutrition Induces Sustained Remission in a Randomized Controlled Trial Study, Aug 2019 Read the paper: Crohn's Disease Exclusion Diet Plus Partial Enteral Nutrition Induces Sustained Remission in a Randomized Controlled Trial
  24. ECCO and ESPGHAN (J Crohns Colitis) Management of pediatric Crohn's disease: an ECCO-ESPGHAN guideline update Guideline, Aug 2026 Read on the ECCO and ESPGHAN (J Crohns Colitis) website: Management of pediatric Crohn's disease: an ECCO-ESPGHAN guideline update